Fundraising FoxTauC3 Biologics
London · Founded 2019 · Incorporated in United Kingdom · 1 known investors
Find your way into TauC3 Biologics
Sign up to see every warm intro you have to TauC3 Biologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TauC3 Biologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TauC3 Biologics is a biotechnology company developing therapies for neurodegenerative diseases, with a focus on tau-related and Alzheimer's disease drug discovery. It brings together drug development and neuroscience expertise to advance treatments for CNS disorders.
Founders & leadership
TauC3 Biologics was founded in 2019 by Daniel G. Chain.
DG
Daniel G. ChainPresident and Chief Executive OfficerDaniel G. Chain is a neuroscientist and President and CEO of TauC3 Biologics, a biotechnology company developing therapies for neurodegenerative diseases including tau-related and Alzheimer's drug discovery. His expertise spans drug discovery and development as well as intellectual property licensing.
SP
Scott PollackScientific/Platform LeaderScott Pollack is a drug discovery scientist with experience in the pharmaceutical and CRO industries, specializing in biophysical and enzymology-based approaches. He leads platform development at TauC3 Biologics, a biotechnology company focused on tau-related and Alzheimer's disease therapies.
PM
Peter McGowanCFO
SV
Shafique ViraniNamed on SEC filing
JG
John GogolNamed on SEC filing
BG
Bia GoncalvesDirector of Scientific Communications
Board
PS
AJ
Andrew J. HeathChairman
Investors · 1
Funding
SEC filings, press & company announcements$868.2K disclosed across 4 of 5 rounds · 2020–2025
- Undisclosed amountSeries ADec 2025Source ↗
▶$690KraisedMar 2022 · BiotechnologyRule 506(b)
▶$690KraisedMar 2022 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Parag SaxenaDirector
- John GogolDirector
- Daniel ChainExecutive Officer, Director
- Andrew HeathDirector
- Shafique ViraniDirector
- Offering amount
- $690K
- Amount sold
- $690K
- First sale
- Jan 2022
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
▶$18.7KraisedDec 2020 · 1 investors · BiotechnologyRule 506(b)
▶$18.7KraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John GogolDirector
- Shafique ViraniDirector
- Andrew HeathDirector
- Daniel ChainExecutive Officer, Director
- Parag SaxenaDirector
- Offering amount
- $18.7K
- Amount sold
- $18.7K
- First sale
- Dec 2020
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
▶$11KraisedNov 2020 · 2 investors · BiotechnologyRule 506(b)
▶$11KraisedNov 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel ChainExecutive Officer, Director
- Andrew HeathDirector
- John GogolDirector
- Parag SaxenaDirector
- Shafique ViraniDirector
- Offering amount
- $500K
- Amount sold
- $11K
- First sale
- Oct 2020
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
▶$148.5KraisedNov 2020 · 4 investors · BiotechnologyRule 506(b)
▶$148.5KraisedNov 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel ChainExecutive Officer, Director
- Andrew HeathDirector
- Shafique ViraniDirector
- Parag SaxenaDirector
- John GogolDirector
- Offering amount
- $148.5K
- Amount sold
- $148.5K
- First sale
- Oct 2020
- Incorporated
- Other, United Kingdom, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as TauC3 Biologics.
In the news
Frequently asked questions
- What does TauC3 Biologics do?
- TauC3 Biologics is a biotechnology company developing therapies for neurodegenerative diseases, with a focus on tau-related and Alzheimer's disease drug discovery. It brings together drug development and neuroscience expertise to advance treatments for CNS disorders.
- Who founded TauC3 Biologics?
- TauC3 Biologics was founded by Daniel G. Chain in 2019.
- Who are TauC3 Biologics's investors?
- TauC3 Biologics's investors include Vedanta Capital.
- How much funding has TauC3 Biologics raised?
- TauC3 Biologics has disclosed $868.2K raised across 4 of its 5 known rounds.
- Where is TauC3 Biologics headquartered?
- TauC3 Biologics is headquartered in London.